BRIEF published on 01/09/2025 at 15:35, 1 year 6 months ago Formycon Joins TecDAX Index Stock Market Biosimilars Deutsche Börse TecDax Formycon
PRESS RELEASE published on 01/09/2025 at 15:30, 1 year 6 months ago Formycon included in TecDAX Index of Deutsche Börse Formycon AG to be included in TecDAX Index of Deutsche Börse, enhancing visibility and market position. Company specializes in biosimilars for various disease areas Formycon AG Biosimilars Deutsche Börse TecDAX Index Technology Stocks
BRIEF published on 01/08/2025 at 14:35, 1 year 6 months ago Health Canada Approves Formycon's Biosimilar FYB202/Otulfi® Healthcare Costs Biosimilar Formycon Ustekinumab Canada Approval
PRESS RELEASE published on 01/08/2025 at 14:30, 1 year 6 months ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 1 year 7 months ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
PRESS RELEASE published on 12/11/2024 at 16:26, 1 year 7 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 1 year 7 months ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 7 months ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year 7 months ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
PRESS RELEASE published on 12/05/2024 at 12:55, 1 year 7 months ago Formycon joins the SDAX of the German Stock Exchange Formycon AG joins the SDAX of the German Stock Exchange, enhancing share attractiveness and visibility in the capital market. Key milestone in the company's growth strategy Formycon AG Biosimilars Capital Market SDAX German Stock Exchange
Published on 07/25/2026 at 00:35, 1 day 7 hours ago Pathfinder Ventures Inc. Provides Corporate Update
Published on 07/24/2026 at 23:00, 1 day 9 hours ago NV Gold Announces Closing of Non-Brokered Private Placement
Published on 07/24/2026 at 22:15, 1 day 9 hours ago Gold Terra Announces Closing of First Tranche of C$10.8M LIFE Offering With Strong Participation From Strategic Shareholder David Harquail
Published on 07/24/2026 at 22:05, 1 day 9 hours ago Findev Inc. Announces CCAA Proceedings Involving 1682 Victoria Park Avenue Inc. and Related Party Subordination Arrangement
Published on 07/24/2026 at 20:00, 1 day 12 hours ago Unusual Machines to Announce Second Quarter 2026 Financial Results and Provide Corporate Update
Published on 07/24/2026 at 18:44, 1 day 13 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/24/2026 at 17:50, 1 day 14 hours ago Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 07/24/2026 at 17:40, 1 day 14 hours ago 2CRSi SA: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital as of May 31, 2026.
Published on 07/24/2026 at 18:50, 1 day 13 hours ago Disclosure of transactions in own shares from July 20 to July 24, 2026
Published on 07/24/2026 at 08:00, 2 days ago Accor signs a definitive binding agreement on the sale of its stake in Essendi
